Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISMA: Pioglitazone for Metabolic Syndrome in Type 2 Diabetes
NCT00772174Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of pioglitazone in type 2 diabetes mellitus (T2DM) and metabolic syndrome (2 arms), sponsored by Takeda. Primary endpoint: Increase in High-Density Lipoprotein cholesterol levels at 24 weeks. Started Jan 2007; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic syndrome
Beyond the preview
Go deeper on NCT00772174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772174.